UBS Upgrades Jazz Pharmaceuticals to Buy, Sets $307 Target
UBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
Explore very high cash back cards that come with no annual fee. Maximize your earnings effortlessly.
26,557 articlesUBS has lifted Jazz Pharmaceuticals to Buy with a $307 price target, arguing that improving fundamentals and a stren...
With mortgage rates fluctuating in 2026, some buyers are discovering value in a 15 year path. This report outlines ke...
When choosing where to park money or borrow, the smart move may be to use both banks. Dave Ramsey weighs Navy Federal...
Microsoft sits at a pivotal price near $420 as quarterly results underscore AI momentum and capex intensity. This rep...
A recent social media moment has sparked conversations about money, branding, and opportunities for athletes. See how...
A major fund manager parked 1.3 million shares in a leading self-storage REIT, signaling confidence in the sector. Ex...
The AI-fueled rally pushes major indices higher, yet a tightening macro backdrop and tougher oversight loom as the ma...
Two biotech contenders, Recursion Pharmaceuticals and Summit Therapeutics, face off in a year of uncertainty and oppo...
Bumble reports softer user growth and a hefty impairment bill, even as cash flow improves. The AI-driven reboot is dr...
Modine Manufacturing sits at a compelling crossroads as data centers expand. This primer outlines why investors may w...
Intel's turnaround gains traction amid AI-driven demand and a narrowing foundry loss gap, fueling a debate about whet...
Alphabet reportedly priced a rare 100-year bond to back AI and data-center expansion, a move that stirs debate on lon...